chronic liver disease. burden markedly decreased life expectancy 12th leading cause of death in us...

56
Chronic Liver Disease

Upload: dwain-anthony

Post on 30-Dec-2015

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Chronic Liver Disease

Page 2: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Burden

• Markedly decreased life expectancy• 12th leading cause of death in US• 25,000 deaths annually in US• High morbidity and mortality due to

complications

Page 3: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Cirrhosis

Alcoholic liver disease

Chronic hepatitis B

Chronic hepatitis C

Primary biliary cirrhosis

Primary sclerosing cholangitis

Autoimmune hepatitis

Hereditary hemochromatosis

Wilson’s disease

Alpha1-antitrypsin deficiency

Hepatic Fibrosis

Page 4: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Hepatic fibrosis

• Fibrosis is a wound healing response in which damaged regions are encapsulated by an extracellular matrix or scar

• Develops in almost all patients with chronic liver injury

Page 5: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Cirrhosis

• Late stage of progressive hepatic fibrosis• Generally irreversible in advanced stages

Page 6: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

LFT’s

• LFT is a misleading term – Does not reflect how well the liver is functioning – Abnormal values can be caused by non-hepatic

diseases

Page 7: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

LFT’s

• Enzyme tests: AST, ALT, Alk Phos and GGT• Hepatic Function: Albumin and PT and

Indirect bilirubin• Hepatic transport ability (biliary system):

Direct Bilirubin

Page 8: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Patterns

• Disproportionate elevation of transaminases seen with hepatocellular processes

• Disproportionate elevation of Alk Phos seen in cholestatic process

• Serum Bilirubin can be elevated in both processes, so need to look at direct vs indirect bilirubin to differentiate

Page 9: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Patterns

• Low albumin suggests chronic process • Normal albumin suggests acute process • Elevated PT/INR is either Vit K deficiency (due to

malabsorption of Vit K) or significant hepatocellular dysfunction (inability to make coagulation factors)

• Failure of parenteral Vit K to correct PT indicates significant hepatocellular dysfunction (inability to make coagulation factors).

Page 10: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Patients who lack an apparent cause for cirrhosis should be questioned about lifetime body weight because nonalcoholic steatohepatitis (NASH) has been concluded to be causative in many patients.

Page 11: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

•Ascites• What do we do when a patient presents with

ascites for the first time?

Page 12: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• The cause of new ascites should be evaluated by doing a paracentesis.

Page 13: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• What does a bloody ascitic fluid suggest?

Page 14: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Tumor

Page 15: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• What does a cloudy ascitic fluid suggest?

Page 16: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Infection

Page 17: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• What does a milky ascitic fluid suggest?

Page 18: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Lymphatic obstruction

Page 19: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Approximately 1,500cc of fluid must be present in the abdomen before flank dullness is detected on percussion.

• The fluid wave is not a useful sign but shifting dullness is.

Page 20: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• What is the most common cause of ascites in United States?

Page 21: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• 85% of patients with ascites in the United States have cirrhosis

Page 22: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• What are the tests that we order on the ascites fluid obtained by paracentesis?

Page 23: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• IF uncomplicated cirrhosis ascites is suspected, only cell count and differential, albumin, and total protein concentration are performed on the initial specimen.

Page 24: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• If ascitic fluid infection is suspected (fever, abdominal pain, elevated cell count or unexplained encephalopathy), bacterial culture in blood culture bottles should be performed.

Page 25: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• What can we do to determine the cause of ascites after the ascitic fluid labs are back?

Page 26: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Serum-to ascites albumin gradient (SAAG)

• SAAG= (serum albumin)-(ascitic fluid albumin)

• SAAG > 1.1 indicates portal HTN • SAAG < 1.1 indicates pt does not have

portal HTN

Page 27: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• SAAG >1.1 (portal HTN):- Cirrhosis- Right heart failure- Fulminant liver failure (which also includes

“massive hepatic metastasis”)- Budd-Chiari syndrome- myxedema

Page 28: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• SAAG<1.1:- TB peritonitis- Nephrotic syndrome- Pancreatitis- Peritoneal carcinomatosis

Page 29: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Elevated ascites protein level >=2.5 is seen in all cases of SAAG<1.1 but also in right heart failure.

Page 30: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Ascites PMN count >250 is infection until proven otherwise.

- Do bacterial culture in “blood culture bottles”- Is considered to be spontaneous bacterial

peritonitis (SBP) if there is no evidence of intra-abdominal, surgical treatable source of infection (secondary bacterial peritonitis).

Page 31: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Most of the bacterial cultures of ascitic fluids with PMN>250 will grow bacteria if:

1) The fluid is cultured in two blood culture bottles2) There has been no prior antibiotic treatment and3) There is no other explanation for an elevated

PMN count (e.g. hemorrhagic ascites, peritoneal carcinomatosis, pancreatitis, or peritoneal TB).

Page 32: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• Patients who meet the criteria explained on the previous slide but have negative cultures have been labeled with diagnosis of “culture-negative neutrocytic ascites and should be treated as if they have SBP due to similar mortality as SBP if not treated as such.

Page 33: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Diagnosis of SBP

• Definition: ascitic fluid infection w/o intra-abdominal source of infection

• Positive ascitic fluid culture and/or PMN>250 • Consider secondary bacterial peritonitis if at least

two of the following:– TP >1.0– Glucose <50– LDH > upper limit for serumAND multiple organisms growing on gram stain or

culture.AND PMN >250 (sometimes in thousands).

Page 34: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

                                                       

                                                                       

                                                                                                                             

Page 35: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Antibiotic choice

• Need to cover gut flora as well as Strep and Staph• 3rd generation cephalosporin such as cefotaxime 2g

IV q8hrs• Treat for 5 days and reassess patient– If has had good response, d/c antibiotics– If still has fever or abd pain, re-tap

• PMN <250, stop antibiotics• PMN > pre-treatment level, look for surgical cause• PMN >250 but < pre-treatment level, give 48 hrs antibiotocs and

repeat tap

Page 36: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

SBP Prophylaxis

• Indicated for patients with h/o SBP or variceal bleed

• Proven to decrease mortality, to prevent bacterial infections, and to be cost effective

Page 37: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

SBP Prophylaxis Regimens

• If h/o SBP, Norfloxacin 400 mg qweek or Bactrim DS qday

• If recent variceal bleed, Norfloxacin 400 mg BID or Bactrim DS BID for 7 days

Page 38: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Treatment of ascites of liver disease

• Goal is to minimize edema and ascites w/o intravascular volume depletion

• No evidence that treatment of ascites improves survival, but pt’s feel better

• Treat underlying disorder (eg: Alcohol cessation for alcoholic cirrhosis)

• Avoid NSAID’s• Limit Na to 2g/day

Page 39: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Treatment of ascites of liver disease (continued)

• It is Na restriction and not fluid restriction that results in weight loss

• Fluid restriction is not necessary in treating most patients with cirrhosis or ascites

• Do not attempt to correct the chronic hyponatremia (which is seen often in cirrhotic patients with ascites) unless <120-125 since attempts to rapidly correct hyponatremia with saline can lead to more complications than the hyponatremia itself.

Page 40: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Treatment of ascites of liver disease (continued)

• Start with combination of spironolactone and furosemide (100 mg and 40mg) or spironolactone alone

• Max required doses: spironolactone 400mg/d and furosemide 160 mg/d

• If using combination of spironolactone and furosemide, keep spironolactone to furosemide ratio at 100mg/40mg

• Required wt loss is 300-500g/day without massive edema and 800-1000g/day or more with massive edema

• Oral furosemide is preferred over iv furosemide.

Page 41: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Treatment of ascites of liver disease (continued)

• Do fluid restriction if sodium <120.• Any of the following should lead to cessation

of diuretics:- Encephalopathy- Serum NA <120 despite fluid restriction- Serum creatinine >2.0.

Page 42: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Treatment of large volume ascites

• Treatment of choice is large volume paracentesis:

- Faster, more effective and fewer adverse effects than diuresis

- Diuretics should be given as maintenance therapy to prevent recurrence

Page 43: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Refractory Ascites in liver disease

• <10% of ascites• Defined as fluid overload that:1) Is unresponsive to Na-restricted diet and

high-dose diuretic treatment (400mg/day of spironolactone and 160mg/day of furosemide)

OR2) Recurs rapidly after therapeutic paracentesis.

Page 44: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Treatment of refractory ascites in liver disease

• Options:1) Serial therapeutic paracentesis2) Liver transplantation3) Transjugular intrahepatic portasystemic

stent-shunt (TIPS)4) Peritoneovenous shunt (rarely done)• Referal for liver transplant should not be

delayed.

Page 45: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Complications of cirrhosis

• Variceal hemorrhage• Ascites• Spontaneous bacterial peritonitis• Hepatorenal syndrome• Hepatic encephalopahty• Hepatopulmonary syndrome• Hepatocellular carcinoma

Page 46: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• All patients with chronic liver disease should be checked for hepatitis viral panel, especially for hepatits B and C.

• Vaccination should be given for hepatitis A and B vaccination if they are negative for these types of hepatitis.

Page 47: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• The liver is commonly imaged (usually with Ultrasound) in a patient with cirrhosis with or without ascites. Why?

Page 48: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

• To screen for:- Hepatocellular carcinoma- Portal vein thrombosis- Hepatic vein thrombosis

Page 49: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Case

• 55 yo man with h/o heavy ETOH use presents with abdominal swelling and pain

• What other questions would you ask the patient?• What are you looking for on your exam?

Page 50: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Case

• AST 150, ALT 73, alk phos 153, GGT 320• Bilirubin 4.3, Indirect bilirubin 3.1 • TP 8.3• Albumin 2.2 • INR 1.9• WBC 2.2, H/H 11/33. Plt 78K• Na 130

Page 51: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

What would you do first in the evaluation of this patient??

Page 52: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Paracentesis

• What information do you get from peritoneal fluid analysis?

• What studies do you want to perform on the ascites fluid?

Page 53: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

Ascitic fluid

• Cloudy fluid• Albumin 0.5• TP 0.7• Cell count: 425 WBC, 90% PMN’s• Gram stain: many PMN’s, no bacteria

Page 54: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

How do you interpret the results from your tap?

Page 55: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality

How will you treat the ascites?

Page 56: Chronic Liver Disease. Burden Markedly decreased life expectancy 12th leading cause of death in US 25,000 deaths annually in US High morbidity and mortality